TP53 and colorectal carcinoma: More specifically, studies have shown that oxaliplatin treatment and subsequent resistance in CRC cells alter miRNA expression, affecting signaling pathways within p53, epithelial-to-mesenchymal transition, and cell migration (Tanaka et al., 2015; Gasiulė et al., 2019; Evert et al., 2018).